S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIA non-small-cell lung cancer

The majority of patients with completely resected stage II or IIIA non-small-cell lung cancer (NSCLC) require adjuvant chemotherapy to improve survival following surgery. In the present trial, the 2-year disease-free survival (DFS), and the feasibility and safety of S-1 as an adjuvant chemotherapy f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Clin Oncol
Autori principali: Okuda, Katsuhiro, Yano, Motoki, Tatematsu, Tsutomu, Nakamae, Katsumi, Yamada, Takeshi, Kasugai, Toshio, Nishida, Tsutomu, Sano, Masaaki, Moriyama, Satoru, Haneda, Hiroshi, Kawano, Osamu, Nakanishi, Ryoichi
Natura: Artigo
Lingua:Inglês
Pubblicazione: D.A. Spandidos 2018
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5769234/
https://ncbi.nlm.nih.gov/pubmed/29387399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1481
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi